Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immuneering Corporation IMRX
$8.04
+$0.65 (8.14%)
На 18:04, 12 мая 2023
+266.92%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
207594593.00000000
-
week52high
16.17
-
week52low
3.70
-
Revenue
316952
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-1.56000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| Chardan Capital | Buy | 08 июл 2022 г. | |
| Oppenheimer | Outperform | 01 апр 2022 г. | |
| Piper Sandler | Overweight | 07 янв 2022 г. | |
| Morgan Stanley | Equal-Weight | 24 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Zeskind Benjamin J. | D | 203500 | 2500 | 22 дек 2022 г. |
| Zeskind Benjamin J. | A | 2261852 | 2500 | 22 дек 2022 г. |
| Neufeld Leah R | A | 88600 | 88600 | 31 окт 2022 г. |
| Morales Mallory | A | 10000 | 10000 | 11 авг 2022 г. |
| BERMAN ANN E | A | 14200 | 14200 | 21 июн 2022 г. |
| Feinberg Peter | A | 14200 | 14200 | 21 июн 2022 г. |
| CARPENTER ROBERT J | A | 14200 | 14200 | 21 июн 2022 г. |
| KEATING LAURIE | A | 14200 | 14200 | 21 июн 2022 г. |
| HAUSMAN DIANA | A | 6185 | 6185 | 21 июн 2022 г. |
| Hall Brett Matthew | A | 332685 | 2551 | 25 мая 2022 г. |
Новостная лента
Immuneering To Present at Guggenheim 2023 Oncology Conference
GlobeNewsWire
31 янв 2023 г. в 06:50
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced that management will present at Guggenheim's 2023 Oncology Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Immuneering Announces Participation in November Investor Conferences
GlobeNewsWire
03 ноя 2022 г. в 06:50
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will participate in three November investor conferences to share commentary around the Company's pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer.
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
24/7 Wall Street
21 окт 2022 г. в 20:02
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
24/7 Wall Street
17 окт 2022 г. в 19:41
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.